Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 9.25 | -1.91% | -0.18 |
Earnings due: Aug 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Flat | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 200 DMA | Bullish | -1.91% |
| Alert | Time |
|---|---|
| 200 DMA Support | about 8 hours ago |
| Outside Day | about 9 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| Down 3% | about 10 hours ago |
| Fell Below 200 DMA | about 11 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/06/2024
Iovance Biotherapeutics, Inc. Description
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Oncology Cancer Immunotherapy Cell Therapy Melanoma Antineoplastic Drugs Cancer Cell Lymphocytes Adoptive Cell Transfer Checkpoint Inhibitor Head And Neck Cancer Immunotherapy Products National Cancer Institute Cancer Immunotherapy Product Metastatic Melanoma Pembrolizumab Tumor Infiltrating Lymphocytes Breast And Lung Cancer Ocular Melanoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.33 |
| 52 Week Low | 3.21 |
| Average Volume | 6,882,062 |
| 200-Day Moving Average | 9.24 |
| 50-Day Moving Average | 8.66 |
| 20-Day Moving Average | 8.32 |
| 10-Day Moving Average | 8.81 |
| Average True Range | 0.60 |
| RSI (14) | 57.81 |
| ADX | 23.61 |
| +DI | 36.19 |
| -DI | 15.44 |
| Chandelier Exit (Long, 3 ATRs) | 8.33 |
| Chandelier Exit (Short, 3 ATRs) | 8.96 |
| Upper Bollinger Bands | 9.68 |
| Lower Bollinger Band | 6.96 |
| Percent B (%b) | 0.84 |
| BandWidth | 32.78 |
| MACD Line | 0.13 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.1766 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 10.87 | ||||
| Resistance 3 (R3) | 10.98 | 10.55 | 10.60 | ||
| Resistance 2 (R2) | 10.55 | 10.14 | 10.50 | 10.51 | |
| Resistance 1 (R1) | 9.90 | 9.88 | 9.69 | 9.79 | 10.42 |
| Pivot Point | 9.47 | 9.47 | 9.36 | 9.42 | 9.47 |
| Support 1 (S1) | 8.82 | 9.06 | 8.61 | 8.71 | 8.08 |
| Support 2 (S2) | 8.39 | 8.80 | 8.34 | 7.99 | |
| Support 3 (S3) | 7.74 | 8.39 | 7.90 | ||
| Support 4 (S4) | 7.63 |
